Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2022-06-14 Call Transcript
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Call Transcript Classification · 95% confidence The document is a press release announcing a scheduled conference call to discuss the company's fourth quarter and fiscal year 2022 financial results. It includes details about the call timing, dial-in numbers, webcast information, and a company overview. It explicitly states that the financial statements and MD&A will be filed after market close on June 22, 2022, indicating that this document is an announcement of the upcoming earnings call rather than the call transcript or the financial report itself. The document length is 6191 characters, which is relatively short and consistent with an announcement rather than a full transcript or report. Therefore, this document fits the category of a Call Transcript announcement or Earnings Release announcement. However, since it is announcing the conference call and not the earnings release itself, and it contains no financial results or transcript content, the best fit is Call Transcript (CT) as it is about the scheduled earnings call event.
2022-06-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of pivotal study results for treosulfan in a peer-reviewed journal (American Journal of Hematology). It summarizes clinical trial outcomes, regulatory review status with the FDA, and includes information about a webcast for investors. The document does not contain detailed financial statements or comprehensive financial performance data. It is not an earnings release, annual report, or interim report. It is primarily an announcement of study results publication and regulatory update, typical of a Regulatory Filing (RNS) as it does not fit other specific categories like earnings, management discussion, or capital updates. The document length is over 12,000 characters, but it is a narrative announcement rather than a full report. Therefore, the best classification is Regulatory Filings (RNS).
2022-06-06 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release providing an update on the resubmission of a New Drug Application (NDA) for Treosulfan to the FDA. It discusses regulatory interactions, timelines, and forward-looking statements about the drug approval process. There are no financial statements, detailed financial data, or comprehensive report content. The document is an announcement about regulatory progress and company plans rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a report publication announcement since it does not mention the release of a report but rather an update on a regulatory submission. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related updates that do not fit other specific categories.
2022-05-24 English
News release - English.pdf
Regulatory Filings
2022-04-22 English
News release - English.pdf
Investor Presentation Classification · 95% confidence The document is a press release announcing Medexus Pharmaceuticals' upcoming presentation at the Bloom Burton & Co. Healthcare Investor Conference. It includes details about the event, the company's executives who will present, and background information about the company and the conference organizer. There is no financial data, no detailed report, no voting results, no regulatory filing, and no mention of an attached or published report. The content is primarily an investor presentation announcement, focusing on the company's planned presentation to investors at a conference. Therefore, the most appropriate classification is Investor Presentation (IP). The document length is 6764 characters, which is consistent with a detailed announcement but not a full report or transcript.
2022-04-19 English
News release - English.pdf
Regulatory Filings
2022-03-09 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.